At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 713 enrolled
Drug / intervention
MEDI4736 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)
In Brief
A Phase 3 clinical trial evaluating MEDI4736 and PLACEBO for Non-Small Cell Lung Cancer. Completed, enrolled 713 participants across 236 sites in 26 countries.
Detailed Summary
A Global Study to Assess the Effects of MEDI4736 following concurrent chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesAustralia, Belgium, Canada, Chile, France, Germany, Greece, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Peru, Poland, Singapore, Slovakia, South Africa, South Korea, Spain, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, United States, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartMay 2014
Primary CompletionFeb 2017
Study CompletionAug 2023
TodayJul 2026
First PostedApr 29, 2014
Enrollment StartMay 7, 2014
Primary CompletionFeb 13, 2017
Study CompletionAug 24, 2023
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.2 years ago
Interventions
MEDI4736drug
MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
PLACEBOother
PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).